Question 12

The FDA may require the manufacturer to implement a REMS program.

A REMS (Risk Evaluation and Mitigation Strategy) program is a safety strategy required by the FDA to ensure that the benefits of a medication outweigh its risks, particularly when there is a serious safety concern associated with the drug.

A) MedWatch report

A MedWatch report is a voluntary reporting system used by healthcare professionals and consumers to report adverse events and product problems to the FDA. While it is important for monitoring safety, it does not serve as a required strategy for mitigating risks associated with a medication.

B) failure modes and effects analysis

Failure modes and effects analysis (FMEA) is a proactive approach used to identify and eliminate potential problems in a process before they occur. Although it is a valuable tool in risk management, it is not specifically mandated by the FDA for addressing serious safety concerns in medications.

C) root-cause analysis

Root-cause analysis is a method used to identify the underlying causes of faults or problems. While it can be an important part of quality improvement, it is not a formal requirement set by the FDA for medication safety concerns and does not directly mitigate risks in the same manner as a REMS program.

D) REMS program

A REMS program is specifically designed by the FDA to manage known or potential serious risks associated with a medication. It may include elements such as communication plans, special training for healthcare providers, and restricted distribution to ensure that the medication is used safely and effectively.

Conclusion

The REMS program is the definitive answer as it is a mandated strategy implemented by the FDA specifically to address serious safety concerns associated with medications. Other options, while relevant in different contexts, do not fulfill the specific requirements of risk management as required by the FDA when serious safety issues arise.